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ABSTRACT
Since the 1970s, resistance to antimicrobial agents has become an escalating problem. In the last 25 years,
treatment of infections caused by Gram-positive bacteria has been more problematical than ever, with
infections being caused by multidrug-resistant organisms, particularly methicillin-resistant staphylo-
cocci, penicillin- and erythromycin-resistant pneumococci, and vancomycin-resistant enterococci. There
is a continuing effort in the pharmaceutical industry to develop new antimicrobial agents for the
treatment of resistant infections. Linezolid, quinupristin–dalfopristin, daptomycin, tigecyline, new
glycopeptides and ceftobiprole are the main agents recently introduced or under clinical development.
This review summarises their major properties, the results of recent studies with these agents, and
future treatment possibilities.
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INTRODUCTION
The introduction of benzylpenicillin in the 1940s
ushered in an era of effective treatment of bacte-
rial infections, but it soon became apparent that
some strains of Staphylococcus aureus were
drug-resistant because of the production of
b-lactamase. Since the mid-1970s, resistance to
antimicrobial agents has become an escalating
problem [1]. A striking change during the past
quarter-century has been the increasing impor-
tance of infections caused by Gram-positive bac-
teria, which might have resulted from the
previous emphasis placed on controlling
Gram-negative bacterial infections. Today, it is
necessary to deal with infections caused by
multidrug-resistant organisms, particularly meth-
icillin-resistant staphylococci, penicillin- and
erythromycin-resistant pneumococci, and vanco-
mycin-resistant enterococci (VRE). The emergence
and rapid spread of strains of methicillin-resistant
Staph. aureus (MRSA), which are resistant not only
to all b-lactams, but also to the other main
antibiotic classes, has resulted in an increased
use of glycopeptide antibiotics, i.e., vancomycin
and teicoplanin. Unfortunately, VRE were
detected in 1986, both in France and the UK,
and multidrug-resistant strains of enterococci are
now encountered throughout Europe and the
USA [2–4]. Within 1 year of their initial detection,
resistant strains were associated with infections
in the USA, and they accounted for 26% of
isolates of enterococci from blood in the USA
by the year 2000. Since 1996, vancomycin-
intermediate Staph. aureus (VISA) isolates with
a vancomycin MIC of 8–16 mg ⁄L have been
reported, and this has been followed since 2002
by reports of vancomycin-resistant Staph. aureus
(MIC ‡32 mg ⁄L) [5–8].
As a result of these developments, there is an
urgent need for effective new antimicrobial
agents, as well as for prudent use of existing
agents. Linezolid, quinupristin–dalfopristin, dap-
tomycin, tigecyline, new glycopeptides and cefto-
biprole are the main new agents that have
recently become available for use or are under
clinical development. This review summarises
their properties, the results of recent studies with
these agents, and future treatment possibilities.
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LINEZOLID
Linezolid (Zyvox) is the ﬁrst of a new class of
antimicrobial agents, the oxazolidinones. Linezo-
lid is a synthetic antibiotic that, depending on the
organism and the linezolid concentration, has a
bacteriostatic or bactericidal effect by inhibiting
protein synthesis at the ribosomal level and by
preventing the formation of the protein initiation
complex [9]. Linezolid is active against most
Gram-positive bacteria, including methicillin-sen-
sitive Staph. aureus (MSSA) and MRSA, Strepto-
coccus pneumoniae (including multidrug-resistant
strains), Streptococcus pyogenes and Streptococcus
agalactiae. Rare occurrences of linezolid resistance
among VRE in North America (0.8–1.8%), caused
by a G2576U ribosomal mutation, have been
reported, and an intrinsic resistance gene render-
ing a clinical strain of MRSA resistant to linezolid
has been described [10–13]. Although resistant
strains of Staph. aureus have been reported, lin-
ezolid remains highly active against MRSA
(MIC90 2 mg ⁄L) [12–15].
Linezolid was approved by the US Food and
Drug Administration (FDA) in 2000 for the
treatment of uncomplicated and complicated skin
and soft-tissue infections, including diabetic foot
infections without concomitant osteomyelitis,
community-acquired and nosocomial pneumonia,
and vancomycin-resistant Enterococcus faecium
infections, including cases with concurrent bac-
teraemia [9]. Activity against Nocardia spp. and
Mycobacterium spp. has also been demonstrated,
including cases of central nervous system infec-
tion and infective endocarditis [14–18].
The high bioavailability of linezolid, whether
administered orally or intravenously, with a
standard twice-daily dose of 600 mg, makes it a
suitable alternative for the treatment of infections
that require the prolonged use of antimicrobial
agents [19,20]. Tissue penetration is good, with
marked accumulation in sweat, saliva and epi-
thelial lining. Linezolid is reported to be equally
effective or even superior to vancomycin for the
treatment of pneumonia and soft-tissue infec-
tions [21–23]. However, recent meta-analyses
have suggested that linezolid’s apparent superi-
ority for the treatment of pneumonia and bone
and joint infections has limitations. Cases of
MRSA endocarditis that failed to respond to
linezolid treatment have also been reported
[15,24,25].
Linezolid is generally well-tolerated, with the
most common adverse effects being diarrhoea,
headache and nausea. Like many other antibio-
tics, it may predispose to pseudo-membranous
colitis following the overgrowth of Clostridium
difﬁcile [26]. Myelosuppression (including anae-
mia, leukopenia, pancytopenia, and thrombocy-
topenia) has been reported in patients taking
linezolid. In cases with a known treatment out-
come, the affected haematological parameters
rose to pre-treatment levels when linezolid was
discontinued. Complete blood counts should be
monitored weekly in patients taking linezolid,
and particularly in patients who are prescribed
linezolid for >2 weeks, patients with pre-existing
myelosuppression, patients receiving concomi-
tant drugs that produce bone marrow suppres-
sion, and patients with a chronic infection who
have received previous or concomitant antibiotic
therapy. Discontinuation of linezolid therapy
should be considered for patients who develop,
or have worsening, myelosuppression. Spontane-
ous reports of serotonin syndrome associated
with the co-administration of linezolid and sero-
tonergic agents, including such anti-depressants
as selective serotonin re-uptake inhibitors, have
been reported. Linezolid has not been studied in
patients with uncontrolled hypertension, pheo-
chromocytoma, carcinoid syndrome or untreated
hyper-thyroidism [27].
Lactic acidosis, peripheral neuropathy and
optic neuropathy are other adverse effects of
linezolid treatment. A recent study that compared
linezolid to vancomycin, oxacillin and dicloxacil-
lin (comparator antibiotics) for the treatment of
seriously-ill patients with intravascular catheter-
related bloodstream infections, including patients
with catheter-site infections, reported a higher
mortality rate in the linezolid arm. There was no
difference in the mortality rate of patients with
Gram-positive infections who were treated with
other antibiotics. Furthermore, the mortality rate
was higher only for patients who were infected
only with Gram-negative organisms, or who were
infected with both Gram-positive and Gram-
negative organisms, or who had no infection
when they entered the study and were
treated with linezolid. Therefore, if infection with
Gram-negative bacteria is known or suspected,
appropriate therapy should be started
immediately (http://www.fda.gov/cder/drug/
InfoSheets/HCP/linezolidHCP.htm).
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Linezolid is an effective alternative antimicro-
bial agent for the treatment of Gram-positive
infections, but because of the absence of placebo-
controlled double-blind studies, linezolid should
be used with extreme caution in patients with
vancomycin-induced nephrotoxicity or a docu-
mented absence of response to vancomycin.
QUINUPRISTIN–DALFOPRISTIN
Quinupristin–dalfopristin (Synercid) is a ﬁxed
mixture (30:70) of semi-synthetic streptogramin
derivatives. These compounds enter bacterial cells
by diffusion and bind to different sites on the 50S
ribosomal subunit, resulting in an irreversible
inhibition of bacterial protein synthesis [28]. Dal-
fopristin blocks the reaction catalysed by the
peptidyl transferase catalytic centre of the 50S
ribosome by inhibiting substrate attachment to the
P-site and A-site of the ribosome. Quinupristin
inhibits peptide chain elongation. The synergic
effect of this drug combination appears to result
from the fact that it targets both early and late
stages of protein synthesis [29]. Thus, quinupri-
stin–dalfopristin is bacteriostatic against E. faecium
and bactericidal against MSSA, MRSA and
Strep. pyogenes. It is ineffective against Enterococcus
faecalis. In the USA, the only FDA-approved use of
quinupristin–dalfopristin as an anti-staphylococ-
cal agent is for the treatment of adults with
complicated skin and skin-structure infections
caused by MSSA. Otherwise, the drug is
approved for complicated skin and skin-structure
infections caused by Strep. pyogenes, and for seri-
ous VRE infections associated with bacteraemia
[30]. Resistance in E. faecium was reported by the
SENTRY antimicrobial surveillance programme in
Europe and North America to be 10.0% and 0.6%,
respectively [10].
The results of studies in which the effectiveness
of quinupristin–dalfopristin for the treatment of
skin and soft-tissue infections was compared to
that of other agents have generally been satisfac-
tory, despite the fact that quinupristin–dalfopri-
stin is inferior to other agents for the treatment of
pneumonia and infective endocarditis [24,31].
Quinupristin–dalfopristin can only be admin-
istered by the intravenous route in a dextrose
5% w ⁄ v solution. Drug elimination is through
bile into faeces, but clearance may be slightly
impaired in patients with renal insufﬁciency. The
drug has signiﬁcant toxicity problems, including
arthralgia–myalgia syndrome and venous intoler-
ance. Pain and inﬂammation at the infusion site is
experienced by up to 74% of patients [31–33].
Hyper-bilirubinaemia and liver toxicity can also
occur. Quinupristin–dalfopristin has been shown
to be a major inhibitor of the activity of the
cytochrome P450 3A4 isoenzyme, and drug inter-
actions (especially with cyclosporine) should be
monitored carefully during therapy. Although the
drug itself does not induce QTc prolongation, it
can interfere with the metabolism of other drug
products that are associated with QTc prolonga-
tion [33,34].
Quinupristin–dalfopristin is the ﬁrst parenteral
streptogramin and offers a unique alternative
treatment for infections caused by multidrug-
resistant Gram-positive bacteria, but the broad
spectrum of adverse effects makes it an inferior
choice to other agents.
DAPTOMYCIN
Daptomycin (Cubicin) is the ﬁrst of a new class
of cyclic lipopeptides. This agent is derived from
the fermentation of a strain of Streptomyces ros-
eosporus. Originally developed during the early
1980s, daptomycin was initially shelved because
of concerns about skeletal-muscle toxicity. This
effect was not seen with lower doses, and dapto-
mycin received approval by the FDA in Septem-
ber 2003 for the treatment of complicated skin
and soft-tissue infections.
Daptomycin attaches to the cytoplasmic mem-
brane of Gram-positive bacteria, forming a channel
that allows the efﬂux of potassium, causing depo-
larisation of themembrane, alongwith dysfunction
of macromolecular synthesis and collapse of the
organism without lysis. This mechanism of action
is concentration-dependent, free calcium ion-
dependent, rapid and unique [35]. Some other
bactericidal antibiotics, most notably b-lactams,
cause bacterial cells to lyse. This is potentially
harmful, as it may release bacterial endotoxins and
other inﬂammatory cell components into the
circulation, triggering cytokine cascades, and
potentially leading to septic shock and multiple
organ failure [36]. The antimicrobial effect of
daptomycin is concentration-dependent, with
the optimal dose for serious bloodstream and
endovascular infections reported to be 6 mg ⁄ kg
once-daily. The recommended dose for skin and
skin-structure infections is 4 mg ⁄ kg once-daily.
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Daptomycin also has a post-antibiotic effect lasting
1.5–6 h [37].
Although daptomycin is approved by the FDA
for the treatment of complicated skin and skin-
structure infections that involve MRSA and
other Gram-positive bacteria, its rapid bacterici-
dal effect makes it appropriate for the treatment
of other kinds of infection. The bactericidal
activity of daptomycin, vancomycin, linezolid
and quinupristin–dalfopristin against MRSA and
VISA has been compared using in-vitro time-kill
studies [38]. Against all organisms tested, dapto-
mycin had bactericidal activity equal to or greater
than that of the other agents [39].
Daptomycin has efﬁcacy comparable to stan-
dard therapy for the treatment of skin and skin-
structure infections. It has been used successfully
to treat bone and joint infections [40,41]. Successful
results have also been reported for the treatment of
bacteraemia and right-sided infective endocarditis,
but not for the treatment of community-acquired
pneumonia. When daptomycin was compared
with standard therapy for bacteraemia and endo-
carditis caused by Staph. aureus, a successful out-
come was documented in 53 of 120 of patients who
received daptomycin, compared with 48 of 115
patients who received standard therapy (44.2% vs.
41.7%, respectively; absolute difference, 2.4%;
95% CI 10.2–15.1) [42–44]. The lack of efﬁcacy of
daptomycin in treating community-acquired
pneumonia is thought to be a consequence of a
reduction of daptomycin activity in the presence of
lung surfactant [45].
Resistance to daptomycin is rare. Spontaneous
resistance is uncommon, emerging in vitro at a rate
of <1 · 10)10, but resistance can be induced by
serial passage in increasing concentrations of the
antibiotic [46]. There have been several reports of
daptomycin resistance emerging in clinical iso-
lates of MRSA from patients who received pro-
longed treatment [47,48]. The once-daily dosing
schedule and the favourable safety proﬁle (except
for some concerns regarding rhabdomyolysis
and neuropathy) make daptomycin an attractive
option for the treatment of Gram-positive infec-
tions [44].
TIGECYCLINE
Tigecycline (Tygacil) is a new, semi-synthetic
glycylcycline, which is a new class of antimicro-
bial agent. Glycocides are derivatives of tetracy-
clines, and have broad-spectrum activity against
susceptible and multidrug-resistant strains of
bacteria. Tigecycline, the ﬁrst glycylcycline, dem-
onstrates potent in-vitro activity against a wide
range of Gram-positive and Gram-negative bac-
teria, including MRSA and tetracycline-resistant
Staph. aureus, as well as many multidrug-resistant
Gram-negative pathogens and anaerobes [49]. The
potent in-vitro activity of tigecycline resulted in
its approval by the FDA for the treatment of skin,
soft-tissue and intra-abdominal infections [50].
Like tetracycline, tigecycline exerts its mecha-
nism of action by reversibly binding to the 30S
ribosomal subunit and inhibiting protein transla-
tion in bacteria. This blockade prevents the entry
of aminoacyl tRNA molecules into the A-site of
the ribosome, resulting in the loss of peptide
formation [51,52]. Tigecycline is highly effective
in vivo against most Gram-positive organisms, inc-
luding Staph. aureus, coagulase-negative staphy-
lococci, Enterococcus spp., Strep. pneumoniae, and
group A, group B and viridans streptococci. It
also has good in-vitro activity against most Gram-
negative organisms and anaerobes. Interestingly,
some atypical microorganisms, e.g., Mycobact-
erium abscessus, Mycobacterium chelonae, the Myco-
bacterium fortuitum group, Mycobacterium
marinum, Chlamydia pneumoniae, Mycoplasma
hominis, Mycoplasma pneumonia and Ureaplasma
urealyticum, are also susceptible to tigecycline [53].
Tigecycline has demonstrated excellent overall
tissue penetration in animal studies, including
bone, bone marrow, salivary gland, thyroid,
spleen, kidney and cerebrospinal ﬂuid [53].
Phase 3 randomised double-blind studies have
conﬁrmed the efﬁcacy of tigecycline for the
treatment of skin and skin-structure infections,
and for intra-abdominal infections. Sacchidanand
et al. [54] reported that tigecycline was not
inferior to a combination of aztreonam and
vancomycin for the treatment of complicated
skin and skin-structure infections. Cure rates and
microbiological eradication rates were similar for
tigecycline and a comparator group of antibiot-
ics, at 82.9% and 82.3%, respectively [54]. In two
other phase 3 double-blind studies involving 833
clinically evaluable patients (422 treated with
tigecycline and 411 treated with vancomycin and
aztreonam), clinical response rates were similar
for tigecycline (86.5%) (95% CI 82.9–89.6%) and
vancomycin–aztreonam (88.6%) (95% CI 85.1–
91.5%) [55].
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In a pooled analysis of two phase 3 double-
blind trials designed to evaluate the safety and
efﬁcacy of tigecycline in comparison with that of
imipenem–cilastatin, clinical cure rates for the
microbiologically evaluable group among 1642
adults with complicated intra-abdominal infec-
tions were 86.1% for tigecycline and 86.2% for
imipenem–cilastatin (95% CI for the difference
)4.5 to 4.4%; p <0.0001 for non-inferiority) [56].
Similar results were obtained in another study
which demonstrated that tigecycline was not
inferior for treating complicated intra-abdominal
infections [57].
Clinically signiﬁcant organ toxicity has not
been observed in association with tigecycline
use during clinical trials. Nausea and vomiting
are the most common side-effects, and these are
dose-limited and are not diminished by reduc-
ing the rate of drug infusion [58]. The low
potential of the drug for the development of
resistance, which is almost a rule for other
tetracyclines, combined with its broad-spectrum
activity against multidrug-resistant pathogens,
provides key advantages. Therefore, tigecycline
presents a genuinely new therapeutic option for
the treatment of infections caused by multidrug-
resistant bacteria.
NEW GLYCOPEPTIDES
Oritavancin, telavancin and dalbavancin are new
glycopeptides currently in clinical development,
and appear to be potent molecules with favour-
able pharmacokinetic and pharmacodynamic
properties.
Oritavancin
This agent was obtained by reductive alkylation
with 4¢-chloro-biphenylcarboxaldehyde of chloro-
eremomycin, which differs from vancomycin by
the addition of a 4-epi-vancosamine sugar, and
the replacement of vancosamine of the disac-
charide moiety by an epivancosamine [59].
Although oritavancin has a general spectrum
of activity comparable to that of vancomycin, it
offers considerable advantages in terms of
intrinsic activity (especially against streptococci).
Unlike vancomycin, oritavancin can dimerise,
leading to a cooperative interaction with two
stems of the growing peptidoglycan chain. The
lipophilic side-chain assists in membrane-
anchoring by hydrophobic interactions, stabilis-
ing the dimer in the most favourable position.
Evidence also exists for another mechanism of
action of oritavancin, namely inhibition of the
transglycosylation step of cell-wall synthesis
[60,61].
Oritavancin is active against most isolates of
streptococci and staphylococci, as well as Pepto-
streptococcus spp., Propionibacterium acnes, Clos-
tridium perfringens and Corynebacterium jeikeium.
Its activity against enterococci is not affected by
the presence of vanA-, vanB- and vanC-encoded
vancomycin resistance, or by aminoglycoside
resistance. Its activity against pneumococci and
viridans streptococci is not affected by the
presence of intermediate- or high-level penicillin
resistance. In addition, the presence of methicil-
lin resistance does not affect the activity of
oritavancin against Staph. aureus or coagulase-
negative staphylococci. Oritavancin is inactive
against Gram-negative aerobes and anaerobes
[62].
Oritavancin is active in a number of animal
models of infection, including a central venous
catheter-associated infection model in rats (vanco-
mycin-resistant E. faecalis), a rabbit endocarditis
model (MRSA, vancomycin-sensitive and vanco-
mycin-resistant E. faecalis), a neutropenic mouse
thigh model (Staph. aureus ATCC 13709), and a
rabbit meningitis model (penicillin-sensitive
Strep. pneumoniae) [63–68].
In a phase 2 clinical trial involving compli-
cated skin and skin-structure infections, orita-
vancin was not inferior to vancomycin and
cephalexin, but had a shorter mean duration
of activity [69]. In a phase 2 open-label rando-
mised trial comparing oritavancin (5–10 mg ⁄ kg
once-daily for 10–14 days) with vancomycin
(15 mg ⁄kg twice-daily) and a b-lactam for
10–14 days in patients with Staph. aureus-associ-
ated bacteraemia, oritavancin was as effective as
the comparators, with higher clinical and bacte-
riological success in the cohort receiving
10 mg ⁄ kg, and with no evidence of increased
side-effects [70]. The exceptionally long terminal
half-life suggests the existence of storage sites
within the organism. Studies using cultured
macrophages indicate that the drug accumulates
slowly (by an endocytic process), but impor-
tantly, in the lysosomes, from which efﬂux is
extremely slow [71]. The clinical importance of
this property is currently unknown.
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Telavancin
Telavancin (TD-6424) is a semi-synthetic deriva-
tive of vancomycin, possessing a hydrophobic
side-chain on the vancosamine sugar (decylami-
noethyl) and a (phosphonomethyl) aminoethyl
substituent on the cyclic peptidic core [72]. Phar-
macological studies suggest that the enhanced
activity of telavancin against Strep. pneumoniae,
Staph. aureus (to a lesser extent) and staphylococci
and enterococci harbouring the vanA gene cluster
results from a complex mechanism of action,
which, on the basis of data obtained with close
analogues, involves a perturbation of lipid
synthesis and possible membrane disruption [73].
Telavancin is active in vitro against all Gram-
positive pathogens, including vanA-positive
enterococci. As with oritavancin, extreme potency
is observed for streptococci, particularly
Strep. pneumoniae [74]. Telavancin is active in an
in-vitro bioﬁlm model, whereas vancomycin and
a number of other antibiotics were much less
effective [75]. Telavancin is highly effective in
animal models of relevant infections [76–78], and
tissue penetration of telavancin is high after
intravenous administration in healthy subjects
[79]. Telavancin has proven to be effective and
safe for patients with skin and soft-tissue infec-
tions, with cure rates of up to 96%, compared
with 90% for standard therapy. Concerns related
to QTc elevation will be clariﬁed following further
studies [80,81].
Dalbavancin
This agent is a semi-synthetic derivative of the
teicoplanin-related glycopeptide A40925, modi-
ﬁed with an amide appendage at the C-terminus
and an alteration of the hydrophobic acylglucos-
amine substituent. Like teicoplanin, dalbavancin
is active against vanB-positive enterococci, as well
as staphylococci and other important species [73].
The pharmacokinetic proﬁle of dalbavancin is
characterised by a long half-life of c. 7 days. This
allows a once-weekly regimen for the treatment of
infections caused by Gram-positive bacteria. This
weekly regimen may offer certain advantages,
e.g., improved patient compliance and reduced
use of resources compared with antimicrobial
agents administered more frequently [82]. Dalb-
avancin has been shown to be as effective as
linezolid twice-daily for the treatment of compli-
cated skin and skin-structure infections [83], and
is more effective than most anti-Gram-positive
agents, both in vitro and in vivo [84,85].
In addition to complicated skin and skin-struc-
ture infections, dalbavancin has been used to treat
catheter-related bloodstream infection. In a
randomised controlled open-label multicentre
phase 2 trial that involved 75 adult patients with
catheter-related bloodstream infection, the results
were overwhelmingly in favour of dalbavancin,
albeit with limitations [86]. To date, adverse
events have been mild and limited, with the most
common being pyrexia, headache, nausea, oral
candidiasis, diarrhoea and constipation. Conse-
quently, dalbavancin appears to be a promising
antimicrobial agent for the treatment of infections
caused by Gram-positive bacteria.
CEFTOBIPROLE
Ceftobiprole is a novel broad-spectrum b-lactam-
ase-stable parenteral cephalosporin with strong
afﬁnity for the penicillin-binding proteins PBP2a
and PBP2x, responsible for resistance in staphy-
lococci and pneumococci, respectively. Ceftobi-
prole can also bind to relevant penicillin-binding
proteins of resistant Gram-positive and Gram-
negative bacteria, and appears to have a low
ability to select for resistance [87,88]. In-vivo
screening models suggest good activity of cefto-
biprole against Gram-positive and Gram-negative
bacteria. Several animal models have been used in
the evaluation of ceftobiprole, including mouse
sepsis, abscess and pneumonia models, rat endo-
carditis and tissue cage models, and a rabbit
endocarditis model [89,90]. These models suggest
that ceftobiprole should have clinical efﬁcacy as
an empirical treatment for severe clinical infec-
tions.
Several phase 3 studies of ceftobiprole for the
treatment of complicated skin and skin-structure
infections have been performed. One study com-
pared intravenous ceftobiprole (500 mg every
12 h) with intravenous vancomycin (1 g every
12 h) in patients with complicated skin and
skin-structure infections caused by Gram-positive
bacteria. Staphylococci were the predominant
pathogens, and >25% of the microbiologically
evaluable patients had infections caused byMRSA.
In the clinically evaluable population, efﬁcacy and
adverse events were comparable between treat-
ment arms. Additional clinical trials involving
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complicated skin and skin-structure infections and
pneumonia patients are underway to evaluate
ceftobiprole as a treatment for infections caused
by both Gram-positive and Gram-negative bacte-
ria. The broad-spectrum activity of ceftobiprole
may allow it to be used asmonotherapy for serious
nosocomial infections for which combination ther-
apy would otherwise be required [91,92].
CONCLUSIONS
Linezolid, quinupristin–dalfopristin, daptomycin,
tigecycline, new glycopeptides and ceftobiprole
are the most important novel agents that are
currently being considered as alternatives for the
treatment of infections caused by Gram-positive
bacteria. Doripenem, iclaprim (a recent example
of a novel diamonipyrimidine), ranbezolide
(a novel oxazolidinone) and ceftaroline (a novel
cephalosporin with impressive anti-MRSA and
anti-pneumococcal activity) are other agents that
are currently under investigation [93–96].
Changing patterns of resistance have com-
pounded and exacerbated the need for new
antimicrobial agents. Each of the above com-
pounds has its own unique advantages and
disadvantages, so each agent should be used
cautiously when conventional treatment fails. The
appropriate indications and cost-effectiveness of
these molecules will determine future treatment
options. Until then, prudent use of existing
antibiotics, with strict reinforcement of infection
control precautions, should continue to be the
rule in the treatment of Gram-positive infections.
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